Aim of the study?
The cosMOG study will work to find out if an investigational drug, rozanolixizumab, can prolong the time between relapses of inflammation.
The investigational drug will be given weekly as an infusion under the skin.
What is MOG-AD?
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG‑AD) is a rare inflammatory condition that affects the central nervous system, including nerves in the eyes, spinal cord, and brain.
It is thought to be caused by antibodies that mistakenly target healthy proteins in the body instead of harmful germs or viruses.
Why is the cos-MOG trial important?
With no approved treatment options for MOG‑AD, we understand that your treatment journey may not have been an easy one. Clinical research studies (clinical trials), are a necessary and vital step toward understanding rare diseases such as MOG‑AD and how to treat them.
Eligability criteria
The cosMOG study is looking for about 100 people worldwide who:
Are between 18 and 89 years old
Have a confirmed diagnosis of MOG‑AD
Have relapsing MOG‑AD with at least one relapse in the last 12 months
Have a documented positive serum MOG antibody test using a cell-based assay within 6 months prior to randomization
There are additional eligibility criteria you need to meet to be able to participate in the study. The study team will discuss these with you prior to first dosing.
Active trial sites
There are active trial sites worldwide.
To find out if this study could be right for you, please contact the study site nearest you.
If there are no locations near you, please check again later, as a site may become available in the future..
Have any questions
Contact UCBCares® at 844‑599‑CARE (2273)
Email: ucbCARES@ucb.com